Adc Therapeutics SA (NYSE:ADCT)’s traded shares stood at 1.16 million during the latest session, with the company’s beta value hitting 1.54. At the last check today, the stock’s price was $2.60, to imply an increase of 35.16% or $0.68 in intraday trading. The ADCT share’s 52-week high remains $6.04, putting it -132.31% down since that peak but still an impressive 63.85% since price per share fell to its 52-week low of $0.94. The company has a valuation of $250.90M, with an average of 0.46 million shares in intraday trading volume over the past 10 days and average of 397.22K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Adc Therapeutics SA (ADCT), translating to a mean rating of 1.33. Of 7 analyst(s) looking at the stock, 0 analyst(s) give ADCT a Sell rating. 0 of those analysts rate the stock as Overweight while 3 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Adc Therapeutics SA (NYSE:ADCT) trade information
After registering a 35.16% upside in the latest session, Adc Therapeutics SA (ADCT) has traded red over the past five days. The 5-day price performance for the stock is 7.23%, and -18.91% over 30 days. With these gigs, the year-to-date price performance is 56.33%. Short interest in Adc Therapeutics SA (NYSE:ADCT) saw shorts transact 3.16 million shares and set a 8.61 days time to cover.
The extremes give us $7 and $13 for target low and target high price respectively. As such, ADCT has been trading -400.0% off suggested target high and -169.23% from its likely low.
Adc Therapeutics SA (ADCT) estimates and forecasts
Looking at statistics comparing Adc Therapeutics SA share performance against respective industry, we note that the company has outperformed competitors. Adc Therapeutics SA (ADCT) shares are -24.12% down over the last 6 months, with its year-to-date growth rate higher than industry average at 41.16% against 17.50%. The rating firms project that company’s revenue will grow 4.38% compared to the previous financial year.
Revenue forecast for the current quarter as set by 7 analysts is 18.85M. Meanwhile, for the current quarter, a total of 2 analyst(s) estimate revenue growth to 20.27M.Earnings reports from the last fiscal year show that sales brought in 16.79M and 18.05M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 12.27% before jumping 12.29% in the following quarter.
ADCT Dividends
Adc Therapeutics SA has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Adc Therapeutics SA (NYSE:ADCT)’s Major holders
Adc Therapeutics SA insiders hold 21.03% of total outstanding shares, with institutional holders owning 63.13% of the shares at 79.94% float percentage. In total, 63.13% institutions holds shares in the company, led by REDMILE GROUP, LLC. As of 2024-06-30, the company held over 15.27 million shares (or 18.4964% of shares), all amounting to roughly $48.25 million.
The next major institution holding the largest number of shares is PROSIGHT MANAGEMENT, LP with 9.57 million shares, or about 11.5926% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $30.24 million.
